Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell genomics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:FLDM
Previous Symbol
CUSIP34385P10
Phone650-266-6000
Debt
Debt-to-Equity Ratio7.56
Current Ratio1.85
Quick Ratio1.45
Price-To-Earnings
Trailing P/E Ratio-6.54
Forward P/E Ratio-11.11
P/E GrowthN/A
Sales & Book Value
Annual Sales$101.94 million
Price / Sales3.00
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.80 per share
Price / Book9.73
Profitability
EPS (Most Recent Fiscal Year)($1.19)
Net Income$-60,530,000.00
Net Margins-50.46%
Return on Equity-86.00%
Return on Assets-11.01%
Miscellaneous
Employees505
Outstanding Shares39,320,000
Market Cap$305.93 million
OptionableOptionable
Fluidigm (NASDAQ:FLDM) Frequently Asked Questions
What is Fluidigm's stock symbol?
Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."
How were Fluidigm's earnings last quarter?
Fluidigm Co. (NASDAQ:FLDM) announced its quarterly earnings results on Thursday, November, 1st. The medical research company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.20. The medical research company had revenue of $28.96 million for the quarter, compared to analyst estimates of $27.50 million. Fluidigm had a negative return on equity of 86.00% and a negative net margin of 50.46%. View Fluidigm's Earnings History.
When is Fluidigm's next earnings date?
What price target have analysts set for FLDM?
1 analysts have issued 1 year price objectives for Fluidigm's stock. Their predictions range from $6.10 to $6.10. On average, they expect Fluidigm's share price to reach $6.10 in the next year. This suggests that the stock has a possible downside of 21.6%. View Analyst Price Targets for Fluidigm.
What is the consensus analysts' recommendation for Fluidigm?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fluidigm in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fluidigm.
Has Fluidigm been receiving favorable news coverage?
Press coverage about FLDM stock has trended positive this week, according to InfoTrie. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fluidigm earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an effect on the stock's share price in the next several days.
Who are some of Fluidigm's key competitors?
Some companies that are related to Fluidigm include Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Quanterix (QTRX), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Arrayit (ARYC), Aethlon Medical (AEMD), Precipio (PRPO), Scientific Industries (SCND), Pressure Biosciences (PBIO) and PositiveID (PSID).
Who are Fluidigm's key executives?
Fluidigm's management team includes the folowing people:
- Mr. Stephen Christopher Linthwaite, Pres, CEO & Director (Age 45)
- Mr. Vikram Jog, CFO & Principal Accounting Officer (Age 62)
- Mr. Nicholas S. Khadder, Sr. VP, Gen. Counsel & Corp. Sec. (Age 44)
- Mr. Steven C. McPhail, Chief Commercial Officer (Age 64)
- Ms. Mai Chan Yow, MD of Fluidigm Singapore Pte Ltd & EVP of Worldwide Manufacturing - Fluidigm Singapore Pte Ltd (Age 59)
Who are Fluidigm's major shareholders?
Fluidigm's stock is owned by a number of of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (14.89%), Neuberger Berman Group LLC (11.53%), Russell Investments Group Ltd. (10.91%), BlackRock Inc. (5.01%), Vanguard Group Inc (3.59%) and Vanguard Group Inc. (3.59%). Company insiders that own Fluidigm stock include Evan/ Fa Jones, Levin Capital Strategies, LP, Samuel D Colella, Stephen Christopher Linthwaite and Steven Mcphail. View Institutional Ownership Trends for Fluidigm.
Which institutional investors are selling Fluidigm stock?
FLDM stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., BlackRock Inc., TIAA CREF Investment Management LLC, Panagora Asset Management Inc. and Los Angeles Capital Management & Equity Research Inc.. View Insider Buying and Selling for Fluidigm.
Which institutional investors are buying Fluidigm stock?
FLDM stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc., Renaissance Technologies LLC, Primecap Management Co. CA, JPMorgan Chase & Co., Acadian Asset Management LLC, Perkins Capital Management Inc. and Neuberger Berman Group LLC. Company insiders that have bought Fluidigm stock in the last two years include Levin Capital Strategies, LP, Samuel D Colella, Stephen Christopher Linthwaite and Steven Mcphail. View Insider Buying and Selling for Fluidigm.
How do I buy shares of Fluidigm?
Shares of FLDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fluidigm's stock price today?
One share of FLDM stock can currently be purchased for approximately $7.78.
How big of a company is Fluidigm?
Fluidigm has a market capitalization of $305.93 million and generates $101.94 million in revenue each year. The medical research company earns $-60,530,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fluidigm employs 505 workers across the globe.
What is Fluidigm's official website?
How can I contact Fluidigm?
Fluidigm's mailing address is 7000 Shoreline Court Suite 100, South San Francisco CA, 94080. The medical research company can be reached via phone at 650-266-6000.
MarketBeat Community Rating for Fluidigm (NASDAQ FLDM)
MarketBeat's community ratings are surveys of what our community members think about Fluidigm and other stocks. Vote "Outperform" if you believe FLDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
